TrialClinical drug investigation2018

Efficacy and Safety of Neoadjuvant Treatment with Bevacizumab, Liposomal Doxorubicin, Cyclophosphamide and Paclitaxel Combination in Locally/Regionally Advanced, HER2-Negative, Grade III at Premenopausal Status Breast Cancer: A Phase II Study.

Ekaterini C Tampaki et al.PubMed ↗Publisher ↗

No numbers read from the abstract.